27513357|t|Carbon Monoxide Improves Efficacy of Mesenchymal Stromal Cells During Sepsis by Production of Specialized Proresolving Lipid Mediators
27513357|a|Mesenchymal stromal cells are being investigated as a cell-based therapy for a number of disease processes, with promising results in animal models of systemic inflammation and sepsis. Studies are ongoing to determine ways to further improve the therapeutic potential of mesenchymal stromal cells. A gas molecule that improves outcome in experimental sepsis is carbon monoxide. We hypothesized that preconditioning of mesenchymal stromal cells with carbon monoxide ex vivo would promote further therapeutic benefit when cells are administered in vivo after the onset of polymicrobial sepsis in mice. Animal study and primary cell culture. Laboratory investigation. BALB/c mice. Polymicrobial sepsis was induced by cecal ligation and puncture. Mesenchymal stromal cells, mesenchymal stromal cells - conditioned with carbon monoxide, fibroblasts, or fibroblasts - conditioned with carbon monoxide were delivered by tail vein injections to septic mice. The mice were assessed for survival, bacterial clearance, and the inflammatory response during sepsis in each of the groups. Mesenchymal stromal cells were also assessed for their ability to promote bacterial phagocytosis by neutrophils, the production of specialized proresolving lipid mediators, and their importance for mesenchymal stromal cells function using gene silencing. Ex vivo preconditioning with carbon monoxide allowed mesenchymal stromal cells to be administered later after the onset of sepsis (6 hr), and yet maintain their therapeutic effect with increased survival. Carbon monoxide preconditioned mesenchymal stromal cells were also able to alleviate organ injury, improve bacterial clearance, and promote the resolution of inflammation. Mesenchymal stromal cells exposed to carbon monoxide, with docosahexaenoic acid substrate, produced specialized proresolving lipid mediators, particularly D-series resolvins, which promoted survival. Silencing of lipoxygenase pathways (5-lipoxygenase and 12 / 15-lipoxygenase), which are important enzymes for specialized proresolving lipid mediator biosynthesis, resulted in a loss of therapeutic benefit bestowed on mesenchymal stromal cells by carbon monoxide. Taken together, these data suggest that production of specialized proresolving lipid mediators contribute to improved mesenchymal stromal cell efficacy when exposed to carbon monoxide, resulting in an improved therapeutic response during sepsis.
27513357	0	15	Carbon Monoxide	T103	UMLS:C0007018
27513357	16	24	Improves	T033	UMLS:C0184511
27513357	37	62	Mesenchymal Stromal Cells	T017	UMLS:C3178844
27513357	70	76	Sepsis	T038	UMLS:C0243026
27513357	106	118	Proresolving	T033	UMLS:C0243095
27513357	135	160	Mesenchymal stromal cells	T017	UMLS:C3178844
27513357	189	207	cell-based therapy	T058	UMLS:C3658313
27513357	224	241	disease processes	T038	UMLS:C0030660
27513357	258	265	results	T033	UMLS:C2825142
27513357	269	282	animal models	T204	UMLS:C0599779
27513357	312	318	sepsis	T038	UMLS:C0243026
27513357	320	327	Studies	T062	UMLS:C2603343
27513357	369	376	improve	T033	UMLS:C0184511
27513357	406	431	mesenchymal stromal cells	T017	UMLS:C3178844
27513357	435	438	gas	T103	UMLS:C0017110
27513357	453	461	improves	T033	UMLS:C0184511
27513357	486	492	sepsis	T038	UMLS:C0243026
27513357	496	511	carbon monoxide	T103	UMLS:C0007018
27513357	553	578	mesenchymal stromal cells	T017	UMLS:C3178844
27513357	584	599	carbon monoxide	T103	UMLS:C0007018
27513357	655	660	cells	T017	UMLS:C0007634
27513357	678	685	in vivo	T082	UMLS:C1515655
27513357	705	718	polymicrobial	T038	UMLS:C0275524
27513357	719	725	sepsis	T038	UMLS:C0243026
27513357	729	733	mice	T204	UMLS:C0025929
27513357	735	747	Animal study	T204	UMLS:C0683949
27513357	752	772	primary cell culture	T058	UMLS:C1449562
27513357	774	784	Laboratory	T092	UMLS:C0022877
27513357	785	798	investigation	T058	UMLS:C0220825
27513357	800	811	BALB/c mice	T204	UMLS:C0025919
27513357	813	826	Polymicrobial	T038	UMLS:C0275524
27513357	827	833	sepsis	T038	UMLS:C0243026
27513357	849	854	cecal	T017	UMLS:C0007531
27513357	855	863	ligation	T058	UMLS:C0023690
27513357	868	876	puncture	T058	UMLS:C0034117
27513357	878	903	Mesenchymal stromal cells	T017	UMLS:C3178844
27513357	905	930	mesenchymal stromal cells	T017	UMLS:C3178844
27513357	950	965	carbon monoxide	T103	UMLS:C0007018
27513357	967	978	fibroblasts	T017	UMLS:C0016030
27513357	983	994	fibroblasts	T017	UMLS:C0016030
27513357	1014	1029	carbon monoxide	T103	UMLS:C0007018
27513357	1048	1057	tail vein	T017	UMLS:C2985205
27513357	1058	1068	injections	T058	UMLS:C1533685
27513357	1079	1083	mice	T204	UMLS:C0025929
27513357	1089	1093	mice	T204	UMLS:C0025929
27513357	1151	1172	inflammatory response	T038	UMLS:C1155266
27513357	1180	1186	sepsis	T038	UMLS:C0243026
27513357	1210	1235	Mesenchymal stromal cells	T017	UMLS:C3178844
27513357	1294	1306	phagocytosis	T038	UMLS:C0031308
27513357	1310	1321	neutrophils	T017	UMLS:C0027950
27513357	1353	1365	proresolving	T033	UMLS:C0243095
27513357	1408	1433	mesenchymal stromal cells	T017	UMLS:C3178844
27513357	1434	1442	function	T038	UMLS:C0031843
27513357	1449	1463	gene silencing	T038	UMLS:C0598496
27513357	1494	1509	carbon monoxide	T103	UMLS:C0007018
27513357	1518	1543	mesenchymal stromal cells	T017	UMLS:C3178844
27513357	1588	1594	sepsis	T038	UMLS:C0243026
27513357	1626	1644	therapeutic effect	T201	UMLS:C1527144
27513357	1670	1685	Carbon monoxide	T103	UMLS:C0007018
27513357	1701	1726	mesenchymal stromal cells	T017	UMLS:C3178844
27513357	1755	1767	organ injury	T037	UMLS:C0332675
27513357	1769	1776	improve	T033	UMLS:C0184511
27513357	1814	1824	resolution	T038	UMLS:C1514893
27513357	1828	1840	inflammation	T038	UMLS:C0021368
27513357	1842	1867	Mesenchymal stromal cells	T017	UMLS:C3178844
27513357	1879	1894	carbon monoxide	T103	UMLS:C0007018
27513357	1901	1921	docosahexaenoic acid	T103	UMLS:C0556150
27513357	1954	1966	proresolving	T033	UMLS:C0243095
27513357	2006	2015	resolvins	T103	UMLS:C4288292
27513357	2042	2051	Silencing	T038	UMLS:C0598496
27513357	2055	2076	lipoxygenase pathways	T038	UMLS:C1157322
27513357	2078	2092	5-lipoxygenase	T038	UMLS:C1151570
27513357	2097	2099	12	T038	UMLS:C1151569
27513357	2102	2117	15-lipoxygenase	T038	UMLS:C1324412
27513357	2140	2147	enzymes	T103	UMLS:C0014442
27513357	2164	2176	proresolving	T033	UMLS:C0243095
27513357	2260	2285	mesenchymal stromal cells	T017	UMLS:C3178844
27513357	2289	2304	carbon monoxide	T103	UMLS:C0007018
27513357	2372	2384	proresolving	T033	UMLS:C0243095
27513357	2415	2423	improved	T033	UMLS:C0184511
27513357	2424	2448	mesenchymal stromal cell	T017	UMLS:C3178844
27513357	2474	2489	carbon monoxide	T103	UMLS:C0007018
27513357	2507	2515	improved	T033	UMLS:C0184511
27513357	2516	2536	therapeutic response	T201	UMLS:C0521982
27513357	2544	2550	sepsis	T038	UMLS:C0243026